Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Publikováno v:
Cancer Research. 79:1281-1281
The emergence of the T790M gatekeeper mutation in the Epidermal Growth Factor Receptor (EGFR) gene is an important mechanism that can lead to the acquired resistance to EGFR-targeted tyrosine kinase inhibitors used in a subset of non-small cell lung
Autor:
Priya Koppikar, Sichuan Xi, Vivian Wai Yan Lui, Elizabeth G Nelson, Jennifer R. Grandis, David Man, Allison B.J. Tobey, Raymond L. Chai
Publikováno v:
Clinical Cancer Research. 14:7682-7690
Purpose: Signal transducer and activator of transcription 5 (STAT5) is activated in squamous cell carcinoma of the head and neck (SCCHN), where targeting of STAT5 inhibits tumor growth in vitro and in vivo. The role of STAT5 activation in carcinogene
Autor:
Geoff Grandjean, Garth Powis, Roisin Delaney, Lynn Kirkpatrick, Robert Lemos, Martin Indarte, Marco Maruggi
Publikováno v:
Cancer Research. 77:3015-3015
Activating mutations of KRas is the most common proto-oncogenic event in human cancer but there remains no effective therapy for patients harboring mutated KRas (mut-KRas). Despite intense efforts, tight nucleotide binding, few defined pockets, and r
Autor:
Gabriela Garcia, Gavin MacBeath, Olga Burenkova, William Kubasek, Mark Sevecka, Marisa Wainszelbaum
Publikováno v:
Cancer Research. 73:5464-5464
MM-121/SAR 256212 is a fully human anti ErbB3/HER3 antibody that blocks ligand-induced receptor activation. Formation of EGFR/ErbB3 (ErbB1-3) heterodimers has been implicated as a major driver of tumor growth and survival in non-small cell lung cance
Publikováno v:
Clinical Cancer Research. 18:B25-B25
Introduction: The purpose of this study is to investigate the effects of two PI3K pathway inhibitors on a panel of NSCLC cell lines, with a view to developing resistant cell line models, through exposure to the inhibitors over an extended period of t
Autor:
Joseph S. K. Au, William C. Cho
Publikováno v:
Cancer Research. 72:129-129
OBJECTIVE: Recent studies suggested that lung adenocarcinomas in never-smokers have characteristics distinct from those in smokers. miRNAs are important modulators in cellular pathways. In this study, we investigate the expression profile of miRNAs i
Publikováno v:
Clinical Cancer Research. 18:B17-B17
Introduction: EGFR tyrosine kinase inhibitors (EGFR-TKI) are widely used in metastatic non small cell lung cancer (NSCLC). Nevertheless, the majority of patients with wild type EGFR do not respond to these treatments and, in the selected group with E
Publikováno v:
Molecular Cancer Therapeutics. 10:A69-A69
Pancreatic ductal adenocarcinoma (PDA), the fourth-leading cause of cancer related death in the US, remains an incurable disease. Among the most promising targets for new treatments for PDA is the KRAS oncogene since mutations in this gene are found
Autor:
Marielle Fournel, Marja Dubay, Christian Lemoyne, Stephen William Claridge, Arkadii Vaisburg, Michael Mannion, Robert E. Martell, Lubo Isakovic, Oscar Mario Saavedra, Franck Raeppel, Claire Bonfils, Normand Beaulieu, Hélène Ste-Croix, Carole Beaulieu, Stephane Raeppel, Jeffrey M. Besterman, James Wang, Isabelle Dupont, Christiane R. Maroun
Publikováno v:
Cancer Research. 70:3612-3612
MGCD265 is an oral multitargeted receptor tyrosine kinase inhibitor in Phase II clinical development. MGCD265 targets the Met receptor tyrosine kinase and blocks Met activities which contribute to cancer development and progression such as cell proli